DexCom (DXCM) Expected to Post Quarterly Earnings on Thursday

DexCom (NASDAQ:DXCM) is expected to be posting its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $1.2903 billion for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company posted $0.32 earnings per share. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, analysts expect DexCom to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $71.43 on Thursday. DexCom has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a fifty day simple moving average of $72.01 and a 200 day simple moving average of $68.89. The company has a market capitalization of $27.56 billion, a PE ratio of 30.53, a P/E/G ratio of 1.23 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

Analyst Ratings Changes

A number of analysts have commented on the stock. Benchmark reaffirmed a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Sanford C. Bernstein set a $77.00 price objective on DexCom in a research report on Friday, May 1st. Robert W. Baird set a $80.00 price objective on DexCom in a research note on Friday, May 1st. Barclays restated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Finally, Weiss Ratings raised DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.36.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $72.00, for a total value of $1,926,432.00. Following the transaction, the insider directly owned 355,726 shares in the company, valued at approximately $25,612,272. This trade represents a 7.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 71,750 shares of company stock valued at $5,163,241. 0.28% of the stock is owned by insiders.

Hedge Funds Weigh In On DexCom

A number of institutional investors have recently modified their holdings of the company. DV Equities LLC bought a new position in shares of DexCom in the 4th quarter worth $36,000. Aster Capital Management DIFC Ltd bought a new stake in shares of DexCom during the fourth quarter worth about $63,000. Quarry LP acquired a new stake in shares of DexCom in the 3rd quarter worth about $72,000. MUFG Securities EMEA plc acquired a new stake in shares of DexCom in the 2nd quarter worth about $100,000. Finally, Summit Securities Group LLC lifted its position in DexCom by 817.2% in the 4th quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock valued at $78,000 after acquiring an additional 1,046 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.